<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>VARIZIG- human <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>-zoster immune globulin liquid </strong><br>Cangene BioPharma<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use <span class="Bold">VARIZIG<span class="Sup">®</span></span> safely and effectively.  See full prescribing information for <span class="Bold">VARIZIG</span>.<br><span class="Bold">VARIZIG<span class="Sup">® </span>[<span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Varicella Zoster</span> Immune Globulin (Human)]</span><br><span class="Bold">for intramuscular administration only.</span><br><span class="Bold">Sterile Solution for Injection</span><br><br>Initial U.S. Approval: 2012</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Dosage and Administration, Preparation and Handling   </p></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">VARIZIG is a <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Varicella Zoster</span> Immune Globulin (Human) indicated for post-exposure prophylaxis in high risk individuals (<a href="#ID_d51a61d1-32a0-4f10-aaef-76a12b328bd1">1</a>). High risk groups include: </p>
<dl>
<dt> </dt>
<dd><dl>
<dt>∘</dt>
<dd>immunocompromised children and adults,</dd>
<dt>∘</dt>
<dd>newborns of mothers with <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span> shortly before or after delivery, </dd>
<dt>∘</dt>
<dd>premature infants,</dd>
<dt>∘</dt>
<dd>infants less than one year of age, </dd>
<dt>∘</dt>
<dd>adults without evidence of immunity, </dd>
<dt>∘</dt>
<dd>pregnant women. </dd>
</dl></dd>
<dt> </dt>
<dd>VARIZIG administration is intended to reduce the severity of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>.</dd>
</dl>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta"><span class="Bold">Intramuscular use only.</span> </p>
<p class="Highlighta">Dosing of VARIZIG is based on body weight. Administer a single dose of VARIZIG intramuscularly as recommended in the following table (<a href="#ID_228831e4-4717-48cf-bedd-3155e97a4388">2.1</a>): </p>
<table width="100%">
<col width="18%">
<col width="18%">
<col width="18%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="Highlighta"><span class="Bold">Weight of Patient (kg)</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="Highlighta"><span class="Bold">Dose (IU)</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="Highlighta"><span class="Bold">Number of Vials</span> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="Highlighta">≤2.0 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="Highlighta">62.5 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="Highlighta">0.5 </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="Highlighta">2.1–10.0 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="Highlighta">125 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="Highlighta">1 </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="Highlighta">10.1–20.0 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="Highlighta">250 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="Highlighta">2 </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="Highlighta">20.1–30.0 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="Highlighta">375 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="Highlighta">3 </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="Highlighta">30.1–40.0 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="Highlighta">500 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="Highlighta">4 </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="Highlighta">&gt;40.1 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="Highlighta">625 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="Highlighta">5 </p></td>
</tr>
</tbody>
</table>
<p class="Highlighta">Discard any partial vials. </p>
<p class="Highlighta">The intramuscular dose should be divided and administered in two sites, dependent on patient size. Do not exceed 3 mL per injection site (<a href="#ID_f43cd977-c2fe-48ea-b928-e4de654950db">2.2	Administration</a>) </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">VARIZIG is supplied as a sterile solution for intramuscular injection and is available in a single-use vial of 125 IU in 1.2 mL (<a href="#ID_97923008-460a-45d1-8bc3-cc7adce54e68">3</a>). </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt> </dt>
<dd><dl>
<dt>∘</dt>
<dd>History of anaphylactic or severe systemic reactions to human immune globulins (<a href="#ID_71d9a6ef-2c8d-4a43-9c65-f00fd3220bc9">4</a>). </dd>
<dt>∘</dt>
<dd>IgA-deficient patients with antibodies against IgA and a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (<a href="#ID_71d9a6ef-2c8d-4a43-9c65-f00fd3220bc9">4</a>).</dd>
</dl></dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt> </dt>
<dd><dl>
<dt>∘</dt>
<dd>Thrombotic events (<a href="#ID_25044b8a-d135-4679-81e1-0e3795e4b939">5.1</a>)</dd>
<dt>∘</dt>
<dd><span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">Coagulation disorders</span> (<a href="#ID_79d182e1-4036-4a9f-80d1-71678652c4bf">5.2</a>) </dd>
<dt>∘</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> (<a href="#ID_ceb88cdb-d0c0-4f8e-adf5-3df694153aae">5.3</a>) </dd>
<dt>∘</dt>
<dd>Transmissible infectious agents (<a href="#ID_127ebd8a-c9a2-43ea-86ca-4dcecbf62835">5.4</a>) </dd>
</dl></dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions from clinical trials are <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> at the injection site (3%) and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (2%) (<a href="#ID_766ea7e1-6526-4073-8bbb-9a505225dadb">6</a>).  </p>
<p class="Highlighta">To report SUSPECTED ADVERSE REACTIONS, contact Cangene Corporation  at 1-800-768-2304  or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</a> </p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt> </dt>
<dd><dl>
<dt>∘</dt>
<dd>Efficacy of live attenuated virus vaccines may be impaired by immune globulin administration; revaccination may be necessary (<a href="#ID_0ef000b8-8031-430f-8b68-5a3df2b2de2a">7</a>).</dd>
</dl></dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt> </dt>
<dd><dl>
<dt>∘</dt>
<dd>Pregnancy: Use only if clearly needed (<a href="#ID_81c25056-6aa3-4b8d-9906-9088dd097d3f">8.1</a>)</dd>
<dt>∘</dt>
<dd>Nursing Mothers: Caution should be exercised (<a href="#ID_81c25056-6aa3-4b8d-9906-9088dd097d3f">8.3</a>) </dd>
</dl></dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div><div></div></div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 8/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	Preparation and Handling</a></h2>
<h2><a href="#section-2.2" class="toc">2.2	Administration</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1       Thrombotic Events</a></h2>
<h2><a href="#section-5.2" class="toc">5.2	<span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">Coagulation Disorders</span></a></h2>
<h2><a href="#section-5.3" class="toc"> 5.3	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4	Transmissible Infectious Agents</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Clinical Trial Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Immunocompromised Patients</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-12.1" class="toc">14.1Pregnant Women Exposed to <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Varicella Zoster</span> Virus</a></h2>
<h1><a href="#section-13" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-14.2" class="toc">16.2	Storage and Handling</a></h2>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_d51a61d1-32a0-4f10-aaef-76a12b328bd1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">VARIZIG<span class="Sup">®</span> [<span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Varicella Zoster</span> Immune Globulin (Human)] is indicated for post-exposure prophylaxis of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span> in high risk individuals. High risk groups include:</p>
<dl>
<dt>•</dt>
<dd>immunocompromised children and adults,</dd>
<dt>•</dt>
<dd>newborns of mothers with <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span> shortly before or after delivery, </dd>
<dt>•</dt>
<dd>premature infants,</dd>
<dt>•</dt>
<dd>neonates and infants less than one year of age, </dd>
<dt>•</dt>
<dd>adults without evidence of immunity, </dd>
<dt>•</dt>
<dd>pregnant women. </dd>
</dl>
<p>VARIZIG administration is intended to reduce the severity of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>. Administer VARIZIG as soon as possible following <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">varicella zoster</span> virus (VZV) exposure, ideally within 96 hours for greatest effectiveness.</p>
<dl>
<dt>•</dt>
<dd>There is no convincing evidence that VARIZIG reduces the incidence of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> after exposure to VZV.</dd>
<dt>•</dt>
<dd>There is no convincing evidence that established <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> with VZV can be modified by VARIZIG administration. </dd>
<dt>•</dt>
<dd>There is no indication for the <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> use of VARIZIG in immunodeficient children or adults when there is a past history of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>, unless the patient is undergoing bone marrow transplantation.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_861d9492-0e2d-45cb-b886-c84372c82b81"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">For intramuscular use only. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_228831e4-4717-48cf-bedd-3155e97a4388"></a><a name="section-2.1"></a><p></p>
<h2>2.1	Preparation and Handling</h2>
<p class="First">Each vial of VARIZIG contains a minimum potency of 125 IU in 1.2 mL.  </p>
<p>Bring VARIZIG to room temperature prior to use.</p>
<p>Inspect VARIZIG for particulate matter and discoloration prior to administration.  Do not use if the solution is cloudy or contains particulates.</p>
<p>VARIZIG is for single use only.  Discard any unused portion.</p>
<p>Dosing of VARIZIG is based on body weight. Administer a single dose of VARIZIG intramuscularly as recommended in <a href="#_Ref315252776">Table 1</a>. </p>
<p>The minimum dose is 62.5 International Units (IU) for small infants under two kilograms body weight; the maximum dose of 625 IU should be administered for all patients greater than 40 kilograms in weight.</p>
<a name="_Ref315252776"></a><table width="100%">
<caption><span>Table 1 VARIZIG Dose and Volume of Administration</span></caption>
<col width="15%">
<col width="15%">
<col width="17%">
<col width="18%">
<col width="19%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First">Weight of Patient</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First">VARIZIG Dose</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="top"><p class="First">Volume to Administer* (milliliters)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">Kilograms</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">Pounds</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">IU</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">Number of Vials</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">≤2.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">≤4.4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">62.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2.1–10.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">4.5–22.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">125</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">10.1–20.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">22.1–44.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">250</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">20.1–30.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">44.1–66.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">375</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">30.1–40.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">66.1–88.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">500</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">4.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">≥40.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">≥88.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">625</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">6.0</p></td>
</tr>
<tr class="Last"><td class="Toprule" colspan="5" valign="top"><p class="First">*Extractable volumes are confirmed using a 21 gauge needle as per USP General Chapters &lt;1&gt; Injections. </p></td></tr>
</tbody>
</table>
<p>Consider a second full dose of VARIZIG for high risk patients who have additional exposures to <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span> greater than three weeks after initial VARIZIG administration. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f43cd977-c2fe-48ea-b928-e4de654950db"></a><a name="section-2.2"></a><p></p>
<h2>2.2	Administration</h2>
<p class="First">For intramuscular use only. </p>
<p>Divide the intramuscular dose and administer in two or more injection sites, depending on patient size. Do not exceed 3 milliliters per injection site. </p>
<p>Inject into the deltoid muscle or the anterolateral aspects of the upper thigh. Due to the risk of sciatic <span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">nerve injury</span>, do not use the gluteal region as a routine injection site. If the gluteal region is used, only use the upper, outer quadrant.</p>
<p>To prevent the transmission of infectious agents from one person to another, use a new disposable sterile syringe and needle for each individual patient. </p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="ID_97923008-460a-45d1-8bc3-cc7adce54e68"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">VARIZIG is supplied as a sterile solution for intramuscular injection and is available in a single-use vial of 125 IU. Each 125 IU vial of VARIZIG contains less than 156 milligrams of total protein, mostly human immune globulin G (IgG). VARIZIG contains no preservative and is intended for single use only. VARIZIG does not contain mercury. </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_71d9a6ef-2c8d-4a43-9c65-f00fd3220bc9"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<dl>
<dt> </dt>
<dd><dl>
<dt>∘</dt>
<dd>Individuals known to have anaphylactic or severe systemic (<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>) reactions to human immune globulin preparations should not receive VARIZIG.</dd>
<dt>∘</dt>
<dd>IgA-deficient patients with antibodies against IgA and a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> may have an <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span>. </dd>
<dt>∘</dt>
<dd>VARIZIG contains less than 40 micrograms per milliliter of IgA.</dd>
</dl></dd>
</dl>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_e267130b-4a0a-48bc-b4bf-40eb8af42427"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_25044b8a-d135-4679-81e1-0e3795e4b939"></a><a name="section-5.1"></a><p></p>
<h2>5.1       Thrombotic Events</h2>
<p class="First">Thrombotic events may occur during or following treatment with immune globulin products (1,2,3). Patients at risk include those with a history of <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span>, multiple cardiovascular risk factors, advanced age, impaired <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>, <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulation disorders</span>, <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span> of immobilization, and/or known/suspected hyperviscosity. Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity including those with cryoglobulins, fasting chylomicronemia/markedly high triacylglycerols (triglycerides), or monoclonal gammopathies. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_79d182e1-4036-4a9f-80d1-71678652c4bf"></a><a name="section-5.2"></a><p></p>
<h2>5.2	<span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">Coagulation Disorders</span></h2>
<p class="First">Administer VARIZIG intramuscularly only. In patients who have severe <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> or any <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulation disorder</span> that would contraindicate intramuscular injections, only administer VARIZIG if the expected benefits outweigh the potential risks.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ceb88cdb-d0c0-4f8e-adf5-3df694153aae"></a><a name="section-5.3"></a><p></p>
<h2> 5.3	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First">Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> may occur following VARIZIG administration. Administer VARIZIG in a setting with appropriate equipment, medication and personnel trained in the management of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>. In the case of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, discontinue administration of VARIZIG immediately and provide appropriate treatment.</p>
<p>VARIZIG contains trace amounts of IgA (less than 40 micrograms per milliliter). Patients with known antibodies to IgA have a greater risk of severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>. VARIZIG is contraindicated in IgA deficient patients with antibodies against IgA and history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> [see <a href="#ID_71d9a6ef-2c8d-4a43-9c65-f00fd3220bc9">4 CONTRAINDICATIONS</a>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_127ebd8a-c9a2-43ea-86ca-4dcecbf62835"></a><a name="section-5.4"></a><p></p>
<h2>5.4	Transmissible Infectious Agents</h2>
<p class="First">Because VARIZIG is made from human plasma, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. The plasma donors are screened for the presence of certain infectious agents and the manufacturing process for VARIZIG includes measures to inactivate and remove certain viruses [see<a href="#ID_e62ecd97-8d49-40f8-9df7-19aeb24f3876">11 DESCRIPTION</a>]. Despite these measures, products derived from human plasma can still potentially transmit diseases. No cases of transmission of viral diseases, vCJD or CJD have been associated with the use of VARIZIG. </p>
<p>Report all <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> thought by a physician to have been transmitted by VARIZIG to Cangene Corporation at 1-800-768-2304. Discuss the risks and benefits of this product with the patient before administering it to the patient [see <a href="#ID_809000d0-cd0c-4709-9556-7e9f8beeb416">17 PATIENT COUNSELING INFORMATION</a>]. </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_766ea7e1-6526-4073-8bbb-9a505225dadb"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The most serious adverse drug reactions observed in clinical trials for all subjects and patients (n=601) include <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p>The most common adverse drug reactions (reported by ≥ 1% of subjects) observed in clinical trials for all subjects and patients (n=601) are the following:</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4316207" conceptname="Injection site pain">injection site pain</span> (3%), </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (2%),</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (including terms <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> erythematous, <span class="product-label-link" type="condition" conceptid="4196499" conceptname="Vesicular eruption">rash vesicular</span> and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>) (1%),</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (1%),</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> (1%),</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (1%).</dd>
</dl>
<p>All other adverse drug reactions occurred in less than 1%.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a9d97938-6432-445e-a6e0-860c243d4b17"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Clinical Trial Experience</h2>
<p class="First"><span class="Italics">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</span></p>
<p>Six hundred and one (n=601) high risk individuals received VARIZIG intramuscularly in two clinical trials which included pregnant women, infants and immunocompromised pediatric and adult patients. The highest incidence of adverse reactions occurred in pregnant women (n=166), including <span class="product-label-link" type="condition" conceptid="4316207" conceptname="Injection site pain">injection site pain</span> (7%), <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (including terms <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> erythematous, and <span class="product-label-link" type="condition" conceptid="4196499" conceptname="Vesicular eruption">rash vesicular</span>) (4%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (3%), and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (2%).  All other adverse reactions occurred in 1% or less of clinical trial subjects within each high risk group. A single incidence of <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span> (approximately one in 600 patients treated with VARIZIG) was observed in an immunocompromised adolescent patient. </p>
<p>There were eight reported adverse events associated with  the coagulation system including, <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (n=1), <span class="product-label-link" type="condition" conceptid="436093" conceptname="Disseminated intravascular coagulation">disseminated intravascular coagulation</span> (n=1) , <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span> (n=2), <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulopathy</span> (n=2), <span class="product-label-link" type="condition" conceptid="443752" conceptname="Ventricular hemorrhage">intraventricular hemorrhage</span> (n=1), and <span class="product-label-link" type="condition" conceptid="4301606" conceptname="Pulmonary hemorrhage">pulmonary hemorrhage</span> (n=1)  in 621 subjects in the open-label, Expanded Access Protocol (EAP); the study was not designed to differentiate between adverse events attributed to the underlying medical condition and adverse reactions to VARIZIG. </p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_0ef000b8-8031-430f-8b68-5a3df2b2de2a"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">The passive transfer of antibodies with immune globulin administration may impair the efficacy of live attenuated virus vaccines such as <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, <span class="product-label-link" type="condition" conceptid="4273323" conceptname="Rubella">rubella</span>, <span class="product-label-link" type="condition" conceptid="4290000" conceptname="Mumps">mumps</span> and <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>. Defer vaccination with live virus vaccines until approximately three months after VARIZIG administration. Inform the immunizing physician of recent therapy with VARIZIG so that appropriate measures can be taken [see<a href="#ID_809000d0-cd0c-4709-9556-7e9f8beeb416">17 PATIENT COUNSELING INFORMATION</a>].</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ID_cf035f96-3a83-4ed5-9501-7837cbdb0ebe"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_81c25056-6aa3-4b8d-9906-9088dd097d3f"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy category C. Animal reproduction studies have not been conducted with VARIZIG. It also is not known whether VARIZIG can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. VARIZIG should be given to a pregnant woman only if clearly needed. </p>
<p>The safety and effectiveness of VARIZIG have been evaluated for post-exposure prophylaxis in clinical trials in 166 pregnant women [see <a href="#ID_766ea7e1-6526-4073-8bbb-9a505225dadb">6 ADVERSE REACTIONS</a> and <a href="#ID_772add7e-49f5-49b6-b082-46cb76606bce">14 CLINICAL STUDIES</a>].</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_a05d26ff-0e70-4b04-aab1-f30f06844770"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether VARIZIG is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when VARIZIG is administered to a nursing mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_ba959c44-c946-48c0-95d2-00ad8e349aa6"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The dosing recommendations in the treatment of pediatric patients are by body weight [see <a href="#ID_861d9492-0e2d-45cb-b886-c84372c82b81">2 DOSAGE AND ADMINISTRATION</a>].  </p>
<p>The safety and effectiveness of VARIZIG have been evaluated for post-exposure prophylaxis in the VARIZIG expanded access clinical trial in 374 pediatric patients, including immunocompromised pediatric patients: </p>
<dl>
<dt>•</dt>
<dd>94  preterm newborns and infants,</dd>
<dt>•</dt>
<dd>53 term newborns,</dd>
<dt>•</dt>
<dd>45 infants and toddlers,</dd>
<dt>•</dt>
<dd>176 children and,</dd>
<dt>•</dt>
<dd>43 adolescents.</dd>
</dl>
<p>In the EAP, follow up data were available for 110 VARIZIG treatments in infants (including newborns, pre-term infants, and infants &lt;1 year old). Three severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> were reported, all three with pox count &gt;100, one of which also had <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> and another one also developed probable <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span> <span class="product-label-link" type="condition" conceptid="378143" conceptname="Encephalitis">encephalitis</span>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_e0ec062a-8c6d-451b-9b7c-500343ac26e2"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies of VARIZIG administered intramuscularly for post-exposure prophylaxis did not include sufficient numbers of geriatric subjects (aged 65 and over) to determine whether they respond differently from younger subjects. </p>
<p>Use caution when administering VARIZIG to patients age 65 and over who are judged to be at increased risk of thrombotic events [see <a href="#ID_e267130b-4a0a-48bc-b4bf-40eb8af42427">5 WARNINGS AND PRECAUTIONS</a>]. Do not exceed recommended doses and administer VARIZIG intramuscularly only.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8632ce9e-e442-4663-a7b3-7cc1463b5f08"></a><a name="section-8.5"></a><p></p>
<h2>8.6 Immunocompromised Patients</h2>
<p class="First">In the EAP, both adult (n=37) and pediatric immunocompromised subjects (n=235) were treated.  Twelve immunocompromised subjects developed clinical <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span> and none developed <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span> <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>; however at least five are reported to have received concomitant acyclovir and due to incomplete reporting, it is not known if others also received acyclovir.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID_32ee3844-cca0-4b12-a281-70139787f50e"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Manifestations of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of VARIZIG administered intramuscularly are expected to be <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> at the injection site.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_e62ecd97-8d49-40f8-9df7-19aeb24f3876"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">VARIZIG [<span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Varicella Zoster</span> Immune Globulin (Human)] is a solvent/detergent-treated sterile liquid preparation of purified human immune globulin G (IgG) containing antibodies to <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">varicella zoster</span> virus (anti-VZV). VZV is the causative agent of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span>. VARIZIG is prepared from plasma donated by healthy, screened donors with high titers of antibodies to VZV, which is purified by an anion-exchange column chromatography manufacturing method. This donor selection process includes donors with high anti-VZV titers due to recent natural <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> by VZV, or due to recurrent zoster <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (<span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">shingles</span>).</p>
<p>VARIZIG is intended for single use and should be administered intramuscularly [see 2 DOSAGE AND ADMINISTRATION].</p>
<p>The product potency is expressed in IU by comparison to the World Health Organization (WHO) international reference preparation for anti-VZV immune globulin. Each vial contains 125 IU of anti-VZV. VARIZIG is formulated with 10% maltose and 0.03% polysorbate 80. VARIZIG has a pH of 5.0 – 6.5 and contains no preservative. </p>
<p>The presence of anti-Protein S antibodies has been reported to arise transiently in patients after VZV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (4).  Low levels of anti-Protein S antibodies have been reported in VARIZIG.  </p>
<p>The source plasma used in the manufacture of this product was tested by FDA licensed nucleic acid testing (NAT) for human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus-1 (HIV-1), <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus (HBV) and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C virus (HCV) and found to be negative. Plasma also was tested by in-process NAT for <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> A virus (HAV) and parvovirus B19 (B19) via minipool testing; the limit for B19 in the manufacturing pool is set not to exceed 10<span class="Sup">4</span> IU of B19 DNA per milliliter.</p>
<p>The manufacturing process contains two steps implemented specifically for virus clearance. The solvent/detergent step (using tri-n-butyl phosphate and Triton<span class="Sup">®</span> X-100) is effective in the inactivation of enveloped viruses, such as HBV, HCV and HIV-1. Virus filtration, using a Planova<span class="Sup">®</span> 20N virus filter, is effective for the removal of viruses based on their size, including some non-enveloped viruses. These two viral clearance steps are designed to increase product safety by reducing the risk of transmission of enveloped and non-enveloped viruses. In addition to these two specific steps, the process step of anion-exchange chromatography was identified as contributing to the overall viral clearance capacity for small non-enveloped viruses.</p>
<p>The inactivation and reduction of known enveloped and non-enveloped model viruses were validated in laboratory studies as summarized in <a href="#_Ref399412488">Table 2</a>. The viruses employed for spiking studies were selected to represent those viruses that are potential contaminants in the product, and to represent a wide range of physiochemical properties in order to challenge the manufacturing process’s ability for viral clearance in general.</p>
<a name="_Ref399412488"></a><table width="450.75pt">
<caption><span>Table 2 Virus Reduction Values (Log<span class="Sub">10</span>) Obtained through Validation Studies</span></caption>
<col width="18%">
<col width="11%">
<col width="11%">
<col width="13%">
<col width="10%">
<col width="0%">
<col width="9%">
<col width="10%">
<col width="10%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="top"><p class="First"><span class="Bold">Enveloped</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="5" valign="top"><p class="First"><span class="Bold">Non-Enveloped</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Genome</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">RNA</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">DNA</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="top"><p class="First"><span class="Bold">RNA</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">DNA</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Virus</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">HIV-1</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">BVDV</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">PRV</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">HAV</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">EMC</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">MMV</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">PPV</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Family</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">retro</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">flavi</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">herpes</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="top"><p class="First">picorna</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First">parvo</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Size (nm)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">80–100</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">50–70</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">120–200</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First">25–30</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">30</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">20–25</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">18–24</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Anion Exchange Chromatography (partitioning)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="top"><p class="First">Not evaluated</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First">2.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">n.e.</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3.4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">n.e.</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">20N Filtration (size exclusion)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">≥4.7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">≥3.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">≥5.6*</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First">n.e.</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">4.8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">n.e.</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">4.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Solvent/Detergent (inactivation)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">≥4.7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">≥7.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">≥5.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="5" valign="top"><p class="First">Not evaluated</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Total Reduction (log10)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">≥9.4</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">≥10.8</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">≥11.1</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">2.3</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">4.8</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">3.4</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">4.1</span></p></td>
</tr>
<tr><td class="Toprule" colspan="9" valign="top"><p class="First">*The PRV was retained by the 0.1 µm pre-filter during the virus validation. Since manufacturing employs a 0.1 µm pre-filter before the 20N filter, the claim of  ≥5.6 reduction is considered applicable.</p></td></tr>
<tr><td colspan="9" valign="top"><p class="First">Abbreviations:</p></td></tr>
<tr><td colspan="9" valign="top"><p class="First">HIV-1: human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus-1; relevant virus for human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus-1 and model for HIV-2</p></td></tr>
<tr><td colspan="9" valign="top"><p class="First">BVDV: bovine viral <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> virus; model virus for <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C virus (HCV) and West Nile virus (WNV) </p></td></tr>
<tr><td colspan="9" valign="top"><p class="First">PRV: pseudorabies virus; model for large enveloped DNA viruses, including herpes</p></td></tr>
<tr><td colspan="9" valign="top"><p class="First">HAV: human <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> A virus; relevant virus for HAV and model for small non-enveloped viruses in general</p></td></tr>
<tr><td colspan="9" valign="top"><p class="First">EMC: encephalomyocarditis virus; model for HAV and for small non-enveloped viruses in general</p></td></tr>
<tr><td colspan="9" valign="top"><p class="First">MMV: murine minute virus; model for human parvovirus B19 and for small non-enveloped viruses in general</p></td></tr>
<tr class="Last"><td colspan="9" valign="top"><p class="First">n.e.: not evaluated</p></td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_e1bf8633-81e8-4fed-9e6e-4391676e3ad5"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_8798c6e0-a38d-412d-976d-894863ac246d"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">VARIZIG provides passive immunization for non-immune individuals exposed to VZV, reducing the severity of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (5).</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_5cd09292-ebcd-44a9-b342-1c737df86602"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">In a comparative pharmacokinetic clinical trial, 35 volunteers were administered an intramuscular dose of 12.5 IU/kg of VARIZIG (n=18) or the comparator product VZIG (n=17). The dose of 12.5 IU/kg of VZIG or VARIZIG given to the subjects was based on the assumption that the potency was similar for both products. For the bioequivalence analysis, a potency correction factor was applied (concentrations of VARIZIG were multiplied by 2.3) to account for higher measured potency of the comparator product. The mean peak concentration (C<span class="Sub">max</span>) of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span> antibodies occurred within five days of administration for both products (<a href="#_Ref343717293">Table 3</a>). In the trial, baseline levels of anti-VZV antibodies ranged from 0 to 720 mIU/mL, therefore baseline levels were taken into account for pharmacokinetic calculations, to better represent the indicated population. After potency correction, baseline correction, and exclusion of subjects with baseline values of anti-VZV antibody levels of &gt;200 mIU/mL, the two products were pharmacokinetically comparable.  </p>
<a name="_Ref343717293"></a><table width="100%">
<caption><span>Table 3 Pharmacokinetic Comparison of VARIZIG and VZIG</span></caption>
<col width="21%">
<col width="22%">
<col width="25%">
<col width="28%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">PK Parameters*</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">VARIZIG</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">VZIG</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">Ratio<br>90% Confidence Interval</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">AUC<span class="Sub">0-28 </span></p>
<p>(mIUxDay/mL)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2472 ± 970</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2347 ± 535</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">84.1–124.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">AUC<span class="Sub">0-84 </span></p>
<p>(mIUxDay/mL)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">4087 ± 1620</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3916 ± 964</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">82.0–125.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">C<span class="Sub">max </span></p>
<p>(mIU/mL)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">136 ± 66</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">138 ± 22</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">76.5–112.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">T<span class="Sub">max</span></p>
<p>(Days)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">4.5 ± 2.8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3.3 ± 1.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">Not applicable</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">t<span class="Sub">1/2</span>**</p>
<p>(Days)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">26.2 ± 4.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">23.1 ± 8.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">Not applicable</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">CL/F </p>
<p>(mL/Day)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.204 ± 0.045</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.199 ± 0.087</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">Not applicable</p></td>
</tr>
<tr><td class="Toprule" colspan="4" valign="top"><p class="First">* Potency and subgroup analysis were implemented for pharmacokinetic calculations. Study subjects with elevated baseline anti-VZV levels (&gt;200 mIU/mL) from both treatment groups were excluded from pharmacokinetic calculations.</p></td></tr>
<tr class="Last"><td colspan="4" valign="top"><p class="First">** The half-life is expected to vary from patient to patient.</p></td></tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID_772add7e-49f5-49b6-b082-46cb76606bce"></a><a name="section-12"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">Click here to enter Clinical Studies</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_095b2839-41d3-4bca-b645-fbbb73367802"></a><a name="section-12.1"></a><p></p>
<h2>14.1Pregnant Women Exposed to <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Varicella Zoster</span> Virus</h2>
<p class="First">A randomized, open-label, multicenter, active controlled clinical trial was conducted in 60 pregnant women without immunity to VZV as confirmed by a latex agglutination test. Patients were stratified on the basis of time from first exposure to <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span> as follows:</p>
<dl>
<dt>•</dt>
<dd>one to four days post-exposure and, </dd>
<dt>•</dt>
<dd>five to 14 days post-exposure.</dd>
</dl>
<p>The women were randomized into one of three study arms as follows:</p>
<dl>
<dt>•</dt>
<dd>a single intravenous dose of 125 IU/10 kg body weight to a maximum dose of 625 IU of VARIZIG,</dd>
<dt>•</dt>
<dd>a single intramuscular dose of 125 IU/10 kg body weight to a maximum dose of 625 IU of VARIZIG or,</dd>
<dt>•</dt>
<dd>a single intramuscular dose of 125 IU/10 kg body weight to a maximum dose of 625 IU of VZIG (licensed comparator product).</dd>
</dl>
<p>Patients were followed for 42 days. </p>
<p>Incidence of clinical <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span> was similar across all treatment groups with an overall incidence of 33%; however, in the subset of 28 subjects with more than 24 hours exposure to <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>, the incidence of clinical <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span> in the combined treatment groups was 64%.</p>
<p>Mean weighted constitutional illness scores (CIS) () were similar across all groups and none of the subjects had serious complications of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>. The small number of subjects in each treatment stratum and the lack of agreed upon pre-specified hypothesis testing precluded formal statistical comparisons between groups.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a938a3d0-2be6-4e06-a165-495d5fccaa7c"></a><a name="section-12.1.1"></a><p></p>
<h3>14.2	High Risk Patients Exposed to <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Varicella Zoster</span> Virus</h3>
<p class="First">An open-label, Expanded Access Protocol (EAP) conducted in the United States of America was designed to provide VARIZIG to high risk individuals who were exposed to <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">varicella zoster</span> virus (VZV).  Although the study was not designed to evaluate efficacy, the objective of the study was to further assess and confirm the safety and efficacy of intramuscular injection of VARIZIG in the prevention or reduction of severity of complications from <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in the indicated high risk populations. Initially, enrolment was limited to allow treatment with VARIZIG only within 96 hours of exposure, but the protocol was amended to expand the treatment window to 10 days post-exposure.</p>
<p>The incidence of clinical <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span> (<span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> lesions), was compared to predefined historical reference rates. The incidence of severe <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span> complications, including <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="378143" conceptname="Encephalitis">encephalitis</span>, severe <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span> with pox counts &gt;100 pox, mortality and all complications was also evaluated. The overall incidence of clinical <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span> was evaluated in an interim analysis, where 10% (31/311) of high risk individuals exposed to VZV and treated with VARIZIG for all combined populations, for whom complete or partial efficacy data was available.  Clinical <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span> was observed in 8.4% (13/154) of immunocompromised pediatric and adult patients, in 6.8 % (5/74) of pregnant women, in 14.8% (12/81) of infants and one healthy adult (<a href="http://">Table 4</a>). Clinical <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span> was more common after prolonged VZV exposure.  The final report confirmed the efficacy results in the interim analysis (<a href="#_Ref395092684">Table 5</a>).  In addition, a comparison of the incidence of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span> based on treatment window revealed that treatment between 5 and 10 days post-exposure was no different from treatment within 96 hours.</p>
<dl>
<dt> </dt>
<dd>Table <a href="#">4</a> 	Comparison of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">Varicella</span> Incidence in Subjects Treated with VARIZIG to Historical Incidence of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">Varicella</span> in Untreated Individuals – Interim analysis</dd>
</dl>
<table width="459pt">
<col width="22%">
<col width="21%">
<col width="6%">
<col width="20%">
<col width="16%">
<col width="12%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">High Risk Population</th>
<th class="Botrule Rrule Toprule" align="center" valign="top">Historical Incidence of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">Varicella</span> in Untreated Individuals</th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">n<span class="Sup">1</span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">Incidence of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">Varicella</span> in VARIZIG-treated Subjects</th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">95% Confidence Interval</th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">p-value<span class="Sup">2</span>
</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Pregnant Women</p></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><p class="First">70%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">74</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">6.8% (n=5)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">(2.2–15.1%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">&lt;0.0001*</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Immunocompromised patients </p></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><p class="First">88%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">154</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">8.4% (n=13)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">(4.6–14.0%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">&lt;0.0001*</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Infants </p></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><p class="First">50%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">81</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">14.8% (n=12)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">(7.9–24.5%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">&lt;0.0001*</p></td>
</tr>
<tr class="Last"><td class="Toprule" colspan="6" valign="top">
<p class="First"><span class="Sup">1 </span>n = number of VARIZIG doses for post-exposure prophylaxis of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span> in efficacy population.</p>
<p><span class="Sup">2</span> One sample two-sided exact binomial test.</p>
<p>* Statistically significant (α=0.05). </p>
</td></tr>
</tbody>
</table>
<dl>
<dt> </dt>
<dd><span class="Bold">Table 	Updated Summary of Incidence of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">Varicella</span> in Subjects Treated with VARIZIG - Final Report</span></dd>
</dl>
<table width="97%">
<col width="39%">
<col width="12%">
<col width="20%">
<col width="29%">
<thead>
<tr class="First">
<th class="Lrule Rrule Toprule" align="left" rowspan="2" valign="top">High Risk Population</th>
<th class="Botrule Lrule Rrule Toprule" align="left" colspan="3" valign="top">All VARIZIG Treated Subjects</th>
</tr>
<tr class="Last">
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">n<span class="Sup">1</span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">Incidence of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">Varicella</span> in VARIZIG-treated Subjects</th>
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top">95% Confidence Interval </th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Pregnant Women</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">137</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">7.3% (n=10)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">(3.6% - 13.0%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Immunocompromised patients</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">269</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">4.5% (n=12)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">(2.3% - 7.7%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Infants including newborns, pre-term infants and infants &lt;1 year</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">105</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">11.4% (n=12)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">(6.1% - 19.1%)</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">1 </span>n = number of VARIZIG doses for post-exposure prophylaxis of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span> in efficacy population</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="ID_afb9912f-e958-442b-b4ad-726dae94f0d7"></a><a name="section-13"></a><p></p>
<h1>15 REFERENCES</h1>
<dl>
<dt>1.</dt>
<dd>Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span>. Neurology. 1994; 44:223-6. </dd>
<dt>2.</dt>
<dd>Woodruff RK, Grigg AP, Firkin FC, Smith IL. Fatal thrombotic events during treatment of <span class="product-label-link" type="condition" conceptid="4028065" conceptname="Autoimmune thrombocytopenia">autoimmune thrombocytopenia</span> with intravenous immunoglobulin in elderly patients. Lancet. 1986; 2:217-8. </dd>
<dt>3.</dt>
<dd>Wolberg AS, Kon RH, Monroe DM, Hoffman M. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J Hematol. 2000; 65:30-4.</dd>
<dt>4.</dt>
<dd>Josephson C, Nuss R, Jacobson L, Hacker MR, Murphy J, Weinberg A et al. The <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">Varicella</span>-Autoantibody Syndrome. Pediatr Res. 2001; 50:345-52.</dd>
<dt>5.</dt>
<dd>CDC. Prevention of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2007; 56(No. RR-4):1-30.</dd>
<dt>6.</dt>
<dd>Koren G, Money D, Boucher M, Aoki F, Petric M, Innocencion G et al. Serum concentrations, efficacy, and safety of a new, intravenously administered <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">varicella zoster</span> immune globulin in pregnant women. J Clin Pharmacol. 2002; 42(3):267-74.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_efa0023a-be68-4290-8f14-d8f72dae5c9a"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_9591720f-7e28-4c07-b754-9aa556e65af4"></a><a name="section-14.1"></a><p></p>
<h2>16.1How Supplied</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f340dc64-2e49-4238-ba10-4cdf2d6f5f7f"></a><a name="section-14.2"></a><p></p>
<h2>16.2	Storage and Handling</h2>
<p class="First">Store VARIZIG at 2 to 8°C (36 to 46°F). Do not freeze. Do not use after expiration date.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_809000d0-cd0c-4709-9556-7e9f8beeb416"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Inform patients of the following: </p>
<dl>
<dt>•</dt>
<dd>VARIZIG is intended to reduce the severity of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Please see your doctor if you develop the signs and symptoms of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>.</dd>
<dt>•</dt>
<dd>VARIZIG is prepared from human plasma and therefore, may contain infectious agents such as viruses that can cause disease.</dd>
<dt>•</dt>
<dd>The risk that products derived from human plasma will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, and by inactivating and/or removing certain viruses during manufacturing.</dd>
<dt>•</dt>
<dd>Despite these measures, products derived from human plasma can still potentially transmit disease.</dd>
<dt>•</dt>
<dd>There is also the possibility that unknown infectious agents may be present in such products.</dd>
</dl>
<p>Tell patients that persons known to have severe, potentially life-threatening reactions to human immune globulin products should not receive VARIZIG or any other immune globulin products unless the risk has been justified.</p>
<p>Tell patients that persons who are deficient in IgA may have the potential for developing anti-IgA antibodies and have severe potentially life threatening <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>. </p>
<dl>
<dt>•</dt>
<dd>In the case of allergic or <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>, administration should be stopped immediately.</dd>
<dt>•</dt>
<dd>In the case of <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, the current medical standards for treatment of <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> should be administered.</dd>
</dl>
<p>Inform patients that administration of immune globulin may interfere with the response to live virus vaccines (e.g. <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, <span class="product-label-link" type="condition" conceptid="4290000" conceptname="Mumps">mumps</span>, <span class="product-label-link" type="condition" conceptid="4273323" conceptname="Rubella">rubella</span> and <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>), and instruct them to notify their immunizing physician of recent therapy with VARIZIG.</p>
<p>VARIZIG® [<span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Varicella Zoster</span> Immune Globulin (Human)] Sterile Solution for Injection and any and all Emergent BioSolutions Inc. brand, product, service and feature names, logos, slogans are trademarks or registered trademarks of Emergent BioSolutions Inc. or its subsidiaries in the United States or other countries. All rights reserved.</p>
<p>PLANOVA<span class="Sup">®</span> is a registered trademark of Asahi Kasei Medical Co., LTD, TRITON<span class="Sup">®</span> is a registered trademark of Union Carbide Corporation.</p>
<p>Manufactured by: </p>
<p>Cangene Corporation, a subsidiary of Emergent BioSolutions Inc. </p>
<p>Winnipeg, Canada R3T 5Y3 </p>
<p>U.S. License No. 1201 </p>
<p>Distributed by: </p>
<p>Cangene bioPharma, Inc., a subsidiary of Emergent BioSolutions Inc.</p>
<p>Baltimore, MD</p>
<p>21230, USA</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_7bcb31a1-163e-4359-a187-f4b6f9c67265"></a><a name="section-16"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure">
<a name="id30843046"></a><img alt="53270-0126-1 Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ac96a331-e2ff-4839-a4d5-fda3d858c969&amp;name=image-01.jpg">
</div>
<div class="Figure">
<a name="id30843039"></a><img alt="Outer Carton Label 53270-0126-2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ac96a331-e2ff-4839-a4d5-fda3d858c969&amp;name=image-03.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VARIZIG 		
					</strong><br><span class="contentTableReg"><span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">varicella zoster</span> immune globulin (human) liquid</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PLASMA DERIVATIVE</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:53270-0126</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HUMAN <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">VARICELLA</span>-ZOSTER IMMUNE GLOBULIN</strong> (HUMAN <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">VARICELLA</span>-ZOSTER IMMUNE GLOBULIN) </td>
<td class="formItem">HUMAN <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">VARICELLA</span>-ZOSTER IMMUNE GLOBULIN</td>
<td class="formItem">1.25 [iU]  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:53270-0126-2</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:53270-0126-1</td>
<td class="formItem">1 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125430</td>
<td class="formItem">05/22/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Cangene BioPharma
							(050783398)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Cangene Corporation (244844056)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Cangene Corporation</td>
<td class="formItem"></td>
<td class="formItem">244844056</td>
<td class="formItem">MANUFACTURE(53270-0126)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>8fb4e8f6-884a-4563-a525-f1ace6e254f9</div>
<div>Set id: ac96a331-e2ff-4839-a4d5-fda3d858c969</div>
<div>Version: 4</div>
<div>Effective Time: 20150806</div>
</div>
</div> <div class="DistributorName">Cangene BioPharma</div></p>
</body></html>
